5 March 2024 - Multiple formulary listings are a step forward to ensuring that post-menopausal women have access to medicines that address the unmet medical needs associated with osteoporosis.
Amgen Canada announced today that Evenity (romosozumab) has been listed for reimbursement on nine of Canada's public formularies. With this announcement most post-menopausal women in Canada will be able to access this biologic treatment.